Saturday 17 October 2026
Export RXRX’s income statement to Excel — free account
Recursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
3.47
0.69
−16.59%
Follow RXRX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 15.25 | 4.92 | 4.54 | 5.60 | 3.79 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 42.81 | 18.23 | 16.75 | 15.74 | 12.36 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 331 | 400 | 500 | 500 | 800 | 600 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.01 | 0.03 | 0.08 | 0.09 | 0.07 | 0.12 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 4 | 10 | 40 | 45 | 59 | 75 | ||||
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | (21.16) | 4.46 | 23.12 | 4.99 | |||||
| EBT | — | — | — | (62) | (87) | (186) | (239) | (332) | (465) | (645) | |||||
| EBT margin, % | — | — | — | (2,668.35) | (2,196.01) | (1,832.18) | (601.05) | (745.10) | (789.93) | (863.53) | |||||
| Net income | — | 0 | — | (62) | (87) | (186) | (239) | (328) | (464) | (645) | |||||
| Depreciation | — | — | — | 2 | 4 | 8 | 12 | 24 | 36 | 84 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.11 | 0.18 | 0.08 | 0.23 | 0.21 | 0.21 | 0.17 | ||||
| Earnings | — | — | — | (2.87) | (3.99) | (1.49) | (1.36) | (1.58) | (1.69) | (1.44) | |||||
| Cash flow | — | — | — | (2.64) | (2.08) | (1.27) | (0.48) | (1.38) | (1.31) | (0.83) | |||||
| Capex | — | — | — | (0.18) | (0.31) | (0.32) | (0.21) | (0.06) | (0.06) | (0.02) | |||||
| Free cash flow | — | — | — | (2.83) | (2.39) | (1.58) | (0.69) | (1.44) | (1.37) | (0.85) | |||||
| Book value | — | — | — | 3.56 | 11.11 | 4.33 | 2.77 | 2.23 | 3.77 | 2.53 | |||||
| Shares, m | — | — | — | 22 | 22 | 125 | 176 | 208 | 274 | 447 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | 111.54 | 111.54 | 283.62 | 33.26 | 46.02 | 31.50 | 24.51 | |||||
| P/B | — | — | — | 0.00 | 0.00 | 5.32 | 2.73 | 4.43 | 1.79 | 1.62 | |||||
| EV/Sales | — | — | — | 79.24 | 79.24 | 232.78 | 19.44 | 37.19 | 21.67 | 14.62 | |||||
| EV/FCF | — | — | — | (6.18) | (6.18) | (11.94) | (6.41) | (5.52) | (3.39) | (2.87) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (57) | (45) | (159) | (84) | (288) | (359) | (372) | ||||
| Capex | — | — | — | (4) | (7) | (40) | (37) | (13) | (17) | (9) | |||||
| Free cash flow | — | — | — | (61) | (52) | (198) | (121) | (300) | (376) | (380) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 70 | 243 | 488 | 470 | 345 | 527 | 665 | ||||
| Total debt | — | — | — | 12 | 11 | 1 | 1 | 1 | 19 | 10 | |||||
| Net debt | — | — | — | (63) | (253) | (517) | (551) | (394) | (578) | (738) | |||||
| Shareholders’ equity | — | — | — | 77 | 242 | 543 | 486 | 463 | 1,035 | 1,131 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (61.01) | (43.50) | (41.03) | (36.52) | (48.42) | (44.11) | (44.12) | ||||
| ROIC | — | — | — | (276.95) | 0.00 | (448.73) | 0.00 | (313.71) | (65.59) | (103.19) | |||||
| ROE | — | — | — | 49.80 | 52.64 | (110.79) | (46.56) | (69.12) | (61.89) | (59.54) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Recursion Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | — (loss-making) | — (loss-making) | −60.10% (below 0%: shrinking) | n/m | −32.03% (below 0%: shrinking) | (49.82%) | (1,759.69%) | |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.9× | 16.5× | +18.87% (above 0%: growing) | +81.25% (above 0%: growing) | +19.08% (above 0%: growing) | 92.12% | 48.19% | Compare |
| HRMY Harmony Biosciences Holdings, Inc. | $2.2B | 12.2× | 9.4× | +30.32% (above 0%: growing) | +88.41% (above 0%: growing) | +16.53% (above 0%: growing) | 75.81% | 34.18% | Compare |
| VRDN Viridian Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | +278.67% (above 0%: growing) | n/m | −41.39% (below 0%: shrinking) | 100.00% | (44,460.56%) | Compare |
| IRON Disc Medicine, Inc. | $2.2B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FTRE Fortrea Holdings Inc. | $2.2B | — (loss-making) | — (loss-making) | −4.52% (below 0%: shrinking) | n/m | +53.15% (above 0%: growing) | 20.52% | 2.18% | Compare |
| NVAX Novavax, Inc. | $2.1B | — (loss-making) | — (loss-making) | −76.30% (below 0%: shrinking) | n/m | +42.95% (above 0%: growing) | 74.87% | (96.84%) | Compare |
| Median of peers | $2.2B | — | — | −4.52% | — | +12.18% | 75.34% | 0.00% |
Recursion Pharmaceuticals, Inc. (RXRX) key facts
- Strength: Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Recursion Pharmaceuticals, Inc. (RXRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, RXRX traded at $3.47, a market capitalization of $2.2 billion.
- Return on equity was −59.5% and debt-to-equity 0.01.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.37 (distress zone) for fiscal 2025.